Roivant Sciences (ROIV) Notes Payables (2022)
Roivant Sciences' (ROIV) quarterly Notes Payables came in at $33.3 million in Q2 2022.
Powered by 
Analysis
Roivant Sciences (ROIV) Notes Payables (2022) Analysis & Trends
Roivant Sciences (ROIV) has reported Notes Payables for 1 consecutive years, with $33.3 million the latest figure, recorded in Q2 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.68 Bn | 197.69 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.84 Bn | 177.66 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.30 Bn | 124.45 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.50 Bn | 74.50 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.49 Bn | 56.31 Bn | 1.37 Bn |
| 6 | Moderna | 55.01 Bn | 49.87 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.08 Bn | 30.77 Bn | 992.69 Mn |
| 8 | Biogen | 31.35 Bn | 30.06 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.87 Bn | 29.87 Bn | 1.16 Mn |
| 10 | Insmed | 27.84 Bn | 26.68 Bn | 358.27 Mn |